Abstract
In this study, we aimed to identify an immune-related signature for predicting prognosis in cutaneous melanoma (CM). Sample data from The Cancer Genome Atlas (TCGA; n = 460) were used to develop a prognostic signature with 23 immune-related gene pairs (23 IRGPs) for CM. Patients were divided into high- and low-risk groups using the TCGA and validation datasets GSE65904 (n = 214), GSE59455 (n = 141), and GSE22153 (n = 79). The ability of the 23-IRGP signature to predict CM was precise, with the stratified high-risk groups showing a poor prognosis, and it had a significant predictive power when used for immune microenvironment and biological analyses. We subsequently established a novel promising prognostic model in CM to determine the association between the immune microenvironment and CM patient results. This approach may be used to discover signatures in other diseases while avoiding the technical biases associated with other platforms.
Highlights
The incidence of cutaneous melanoma (CM) is increasing more rapidly than any other cancer, and accounts for about 132,000 new cases and 65,000 deaths worldwide annually [1]
Filter analysis was applied to establish a prognostic model of 1,811 unique immunity-related genes (IRGs) that were obtained from the ImmPort database
6,800 prognostic immune related gene pairs (IRGPs) were significantly associated with overall survival (OS)
Summary
The incidence of cutaneous melanoma (CM) is increasing more rapidly than any other cancer, and accounts for about 132,000 new cases and 65,000 deaths worldwide annually [1]. CM is the most lethal form of skin cancer and is a serious public health concern. The primary clinical feature of CM is early stage metastasis, which is one of the most significantly increasing cancers in the United States [2]. Siegel et al reported that in 2018, it had been 91,270 new cases and 9,320 deaths in the United States, owing to this disease [3]. As most diagnoses are made in the terminal stage, surgical results are often poor. Chemotherapy is the first line of treatment for CM [4], many cases respond poorly to such regimens due to a high prevalence of adverse drug reactions and resistance to chemotherapeutic agents
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
